Alnylam Pharmaceuticals
Biopharmaceutical company
Based in MA
🤖
AI Overview
With $1.4M in lobbying spend across 27 quarterly filings, Alnylam Pharmaceuticals is a significant lobbying presence.
$1.4M
Total Lobbying Spend
27
Quarterly Filings
1
Lobbying Firms Used
5
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $60K |
| 2019 | $190K |
| 2020 | $150K |
| 2021 | $220K |
| 2022 | $220K |
| 2023 | $220K |
| 2024 | $240K |
| 2025 | $80K |
Lobbying Firms
THE MCMANUS GROUP
What They Lobby For
- Reimbursement and access to novel therapeutics based on RNA interference and related administration costs.
- Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340.
- Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892 - Bipartisan Budget Act of 2018.
- Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. H.R. 2113, Prescription Drug STAR Act of 2019. S. 551, the REFUND Act of 2019.
- Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 2543, the Prescription Drug Pricing Reduction Act of 2019. H.R. 3, the Lower Drug Costs Now Act of 2019.
- Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.
- CY 2021 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, CMS-1730-P RIN 0938-AU-06. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 3129/H.R. 19, the Lower Costs, More Cures Act. Home administration of injectable and infusible drugs including CMS-1744-IFC and CMS-5531-IFC.
- CY 2021 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, CMS-1730-P RIN 0938-AU-06. Implementation of Public Law 115-123.
- CY 2021 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, CMS-1730-P RIN 0938-AU-06. Implementation of Public Law 115-123. Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P). Provisions related to vial wastage rebates in Part B. Most Favored Nation (MFN) Model, (CMS-5528-IFC).
- Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P). Provisions related to vial wastage rebates in Part B. Implementation of Home Infusion Therapy Benefit.
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.